Please use this identifier to cite or link to this item:
Scopus Web of Science® Altmetric
Type: Journal article
Title: Efficacy profiles of Daptomycin for treatment of Iinvasive and noninvasive pulmonary infections with treptococcus pneumoniae
Author: Henken, S.
Bohling, J.
Martens-Lobenhoffer, J.
Paton, J.
Ogunniyi, A.
Briles, D.
Salisbury, V.
Wedekind, D.
Bode-Boger, S.
Welsh, T.
Bange, F.
Welte, T.
Maus, U.
Citation: Antimicrobial Agents and Chemotherapy, 2010; 54(2):707-717
Publisher: Amer Soc Microbiology
Issue Date: 2010
ISSN: 0066-4804
Statement of
Stefanie Henken, Jennifer Bohling, Jens Martens-Lobenhoffer, James C. Paton, A. David Ogunniyi, David E. Briles, Vyvyan C. Salisbury, Dirk Wedekind, Stefanie M. Bode-Böger, Thomas Welsh, Franz C. Bange, Tobias Welte and Ulrich A. Maus
Abstract: Daptomycin is a novel lipopeptide antibiotic with excellent activity against Gram-positive bacterial pathogens, but its therapeutic value for the treatment of invasive pneumococcal disease compared to that for the treatment of pneumococcal pneumonia is incompletely defined. We investigated the efficacy of daptomycin in two models of Streptococcus pneumoniae-induced lung infection, i.e., pneumococcal pneumonia and septic pneumococcal disease. Mice were infected with a bioluminescent, invasive serotype 2 S. pneumoniae strain or a less virulent serotype 19 S. pneumoniae strain and were then given semitherapeutic or therapeutic daptomycin or ceftriaxone. Readouts included survival; bacterial loads; and septic disease progression, as determined by biophotonic imaging. Semitherapeutic daptomycin treatment fully protected the mice against the progression of septic disease induced by serotype 2 S. pneumoniae, while therapeutic treatment of the mice with daptomycin or ceftriaxone led to 70% or 60% survival, respectively. In contrast, mice infected with serotype 19 S. pneumoniae developed severe pneumonia and lung leakage even in the presence of increased intra-alveolar daptomycin levels, resulting in only 40% survival, whereas the ceftriaxone-treated mice had 100% survival. Together, although daptomycin demonstrates little efficacy in the treatment of pneumococcal pneumonia, daptomycin is highly effective in preventing S. pneumoniae-induced septic death, thus possibly offering a therapeutic option for patients with life-threatening septic pneumococcal disease.
Keywords: Animals
Mice, Inbred C57BL
Streptococcus pneumoniae
Pneumococcal Infections
Pneumonia, Pneumococcal
Disease Models, Animal
Anti-Bacterial Agents
Rights: Copyright © 2010, American Society for Microbiology. All Rights Reserved.
DOI: 10.1128/AAC.00943-09
Published version:
Appears in Collections:Aurora harvest 5
Molecular and Biomedical Science publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.